Etsuko Iio

发表

Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma

T. Utsunomiya, T. Ochiya, M. Nojima, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Serum interferon‐gamma‐inducible protein‐10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C

K. Matsuura, T. Joh, Etsuko Iio, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy

K. Matsuura, A. Tsubota, Etsuko Iio, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

H. Nomura, A. Tsubota, Takeshi Matsui, 2016, Journal of Gastroenterology.

Bile acid dysmetabolism in the gut‐microbiota‐liver axis under hepatitis C virus infection

H. Yoshiji, K. Matsuura, H. Nakagawa, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Virological characteristics of hepatitis B genotype G/A2 recombination virus in Japan

W. Sugiura, Susumu Hamada-Tsutsumi, Etsuko Iio, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2019, PloS one.

Pitavastatin inhibits hepatic steatosis and fibrosis in non‐alcoholic steatohepatitis model rats

K. Matsuura, T. Joh, Etsuko Iio, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study

A. Tsubota, T. Ishikawa, Etsuko Iio, 2018, Journal of gastroenterology and hepatology.

Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2018, Hepatology International.

Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all‐oral direct acting antivirals in patients with chronic hepatitis C virus infection

Etsuko Iio, Yasuhito Tanaka, H. Toyoda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan

T. Masaki, J. Tani, Hirohito Yoneyama, 2018, Journal of Gastroenterology.

Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis

T. Ishikawa, Etsuko Iio, Yasuhito Tanaka, 2016, Journal of Gastroenterology.

Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

A. Tamori, Etsuko Iio, Yasuhito Tanaka, 2020 .

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan

A. Tsubota, T. Ishikawa, Etsuko Iio, 2019, Open forum infectious diseases.

Efficacy of direct‐acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Liver Stiffness Measurement Is Useful to Predict Early Recurrence of Hepatocellular Carcinoma after Sustained Virological Responses by Direct Antiviral Agents in Patients with Hepatitis C

Etsuko Iio, Yasuhito Tanaka, M. Shimada, 2018 .

Early recurrence of hepatocellular carcinoma in patients with HCV infection followed by transient elastography for two years after successful treatment with daclatasvir plus asunaprevir

Etsuko Iio, Yasuhito Tanaka, M. Shimada, 2017 .

Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection

K. Matsuura, Etsuko Iio, Yasuhito Tanaka, 2021, PloS one.

Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.

H. Nomura, J. Hayashi, Hwai I. Yang, 2019, Clinical Infectious Diseases.

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study

N. Hotta, T. Okanoue, J. Tani, 2020, Infectious Diseases and Therapy.

Application of a glycoproteomics-based biomarker development method: alteration in glycan structure on colony stimulating factor 1 receptor as a possible glycobiomarker candidate for evaluation of liver cirrhosis.

A. Kuno, M. Mizokami, Etsuko Iio, 2014, Journal of proteome research.

Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial.

T. Joh, Etsuko Iio, S. Nojiri, 2017, Nutrition.

Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C

H. Nomura, H. Yoshiji, N. Enomoto, 2014, Human Genetics.

Gut Dysbiosis Associated With Hepatitis C Virus Infection

H. Yoshiji, Etsuko Iio, Yasuhito Tanaka, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B

K. Matsuura, Koji Fujita, Takeshi Matsui, 2021, PloS one.

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan

K. Chayama, M. Kurosaki, N. Furusyo, 2017, Journal of Gastroenterology.

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene

K. Matsuura, F. Sugauchi, M. Kohara, 2012, Gut.

Changes in serum lipid profiles caused by three regimens of interferon‐free direct‐acting antivirals for patients infected with hepatitis C virus

K. Matsuura, Takeshi Matsui, Etsuko Iio, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection

T. Masaki, A. Morishita, J. Tani, 2020, Journal of gastroenterology and hepatology.

Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan

J. Tani, A. Tsubota, Etsuko Iio, 2019, Journal of viral hepatitis.

Validation of Cross-Genotype Neutralization by Hepatitis B Virus-Specific Monoclonal Antibodies by In Vitro and In Vivo Infection

T. Joh, Susumu Hamada-Tsutsumi, Etsuko Iio, 2015, PloS one.

Characterization of novel entecavir resistance mutations.

Y. Karino, Takeshi Matsui, Etsuko Iio, 2015, Journal of hepatology.

Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema

Y. Takei, J. Tani, A. Tsubota, 2019, Journal of gastroenterology and hepatology.

Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C

M. Kudo, Hobyung Chung, H. Kokuryu, 2017, Digestive Diseases.

Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

A. Tamori, Etsuko Iio, Yasuhito Tanaka, 2020, Hepatology.

High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues

M. Nojima, Etsuko Iio, Yasuhito Tanaka, 2018, Journal of Gastroenterology.

Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?

A. Tamori, Etsuko Iio, Yasuhito Tanaka, 2019, Clinical Journal of Gastroenterology.

Characterization of hepatitis B virus with complex structural variations

K. Matsuura, Etsuko Iio, S. Nojiri, 2018, BMC microbiology.

Novel non-canonical genetic rearrangements termed "complex structural variations" in HBV genome.

T. Joh, Etsuko Iio, S. Nojiri, 2017, Virus research.

Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation.

K. Matsuura, S. Yagi, Etsuko Iio, 2021, Journal of hepatology.

A case of a HBV carrier with HDV superinfection treated by PEG-IFN

K. Matsuura, T. Joh, Etsuko Iio, 2014 .

Characterization of hepatitis B virus with complex structural variations

K. Matsuura, Etsuko Iio, S. Nojiri, 2018, BMC Microbiology.

Complex structural variations in non-human primate hepatitis B virus

K. Matsuura, Etsuko Iio, Yasuhito Tanaka, 2021, Virology journal.

Application of a Newly Developed High-Sensitivity HBsAg Chemiluminescent Enzyme Immunoassay for Hepatitis B Patients with HBsAg Seroclearance

K. Matsuura, F. Sugauchi, T. Joh, 2013, Journal of Clinical Microbiology.

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2017, Journal of Gastroenterology.

A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma

K. Matsuura, F. Sugauchi, Etsuko Iio, 2012 .

Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma

T. Utsunomiya, T. Ochiya, A. Tamori, 2016, Molecular Cancer.

Novel Genetic Rearrangements Termed “Structural Variation Polymorphisms“ Contribute to the Genetic Diversity of Orthohepadnaviruses

K. Matsuura, Etsuko Iio, H. Kataoka, 2019, Viruses.

Hepatitis C Virus Infection

Etsuko Iio, Yasuhito Tanaka, 2019, Human Pathobiochemistry.

Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-word setting: a large, multicenter study from Japan.

T. Masaki, T. Okanoue, A. Morishita, 2020, Journal of gastroenterology and hepatology.

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.

H. Yoshiji, K. Ikeo, N. Enomoto, 2017, Gastroenterology.

Endoscopic Treatment for Repeated Arterial Bleeding with Ulcerative Colitis

F. Fujita, T. Joh, M. Itoh, 2007, Digestive Diseases and Sciences.

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

F. Zoulim, T. Ide, J. Dufour, 2019, Journal of hepatology.

TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy

H. Nomura, K. Matsuura, Takeshi Matsui, 2018, Journal of Gastroenterology.

Genome-Wide Association Study Identi fi es TLL 1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection

H. Yoshiji, K. Ikeo, N. Enomoto, 2017 .

Influence of Genes Suppressing Interferon Effects in Peripheral Blood Mononuclear Cells during Triple Antiviral Therapy for Chronic Hepatitis C

K. Matsuura, T. Joh, T. Fujita, 2015, PloS one.

Noninvasive evaluation of hepatic fibrosis in hepatitis C virus‐infected patients using ethoxybenzyl‐magnetic resonance imaging

K. Matsuura, T. Joh, Etsuko Iio, 2013, Journal of gastroenterology and hepatology.

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

H. Nomura, J. Hayashi, Hwai I. Yang, 2019, Hepatology International.

The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy

S. Iida, Etsuko Iio, Yasuhito Tanaka, 2016, International Journal of Hematology.

Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C

K. Matsuura, T. Joh, Etsuko Iio, 2011, Cancer management and research.

Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C

K. Matsuura, Etsuko Iio, Yasuhito Tanaka, 2018, Open forum infectious diseases.

Case-control study of the RFA therapeutic effect of newly developed 4D US and conventional 2D US

K. Matsuura, T. Joh, Etsuko Iio, 2012, Journal of Medical Ultrasonics.

Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma

T. Utsunomiya, T. Ochiya, M. Nojima, 2016, Molecular Cancer.

Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C

H. Nomura, H. Yoshiji, N. Enomoto, 2015, Human Genetics.

Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA+-M2BP) in Chronic Hepatitis C with Advanced Fibrosis.

K. Matsuura, Etsuko Iio, Yasuhito Tanaka, 2018, Japanese journal of infectious diseases.

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort

H. Nomura, J. Hayashi, Hwai I. Yang, 2020, Hepatology International.

Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.

M. Buti, Rui Huang, Chao Wu, 2023, Hepatology international.

A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony‐stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis

M. Nojima, T. Ide, A. Kuno, 2016, International journal of cancer.

Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma

K. Matsuura, T. Joh, Etsuko Iio, 2012, Cancer management and research.

Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents

K. Matsuura, Etsuko Iio, Katsuya Nagaoka, 2024, Oncology.

MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.

K. Matsuura, Etsuko Iio, Katsuya Nagaoka, 2024, Journal of gastroenterology.